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ABSTRACT
p53 is a transcription factor that regulates important cellular processes related 
to tumor suppression, including induction of senescence, apoptosis, and DNA repair 
as well as the inhibition of angiogenesis and cell migration. Therefore, it is critical 
to understand the molecular mechanism that regulates it. p53 tetramerization is 
a key step in its activation process and the regulation of this oligomerization, an 
important control point. The E3 ubiquitin ligase HERC2 controls the p53 transcriptional 
activity by regulation of its oligomerization state. HERC2-interacting proteins such as 
the adaptor-like protein with six neuralized domains NEURL4 are also candidates to 
regulate p53 activity. Here, we demonstrate the existence of an interaction network 
between NEURL4, HERC2 and p53 proteins. We report a functional interaction between 
NEURL4 and p53, involving the C-terminal region of p53 and the neuralized domains 
3 and 4 of NEURL4. Through this interaction, NEURL4 regulates the transcriptional 
activity of p53. Thus, NEURL4 depletion reduced the transcriptional activity whereas 
NEURL4 overexpression increased it. In both cases, p53 stability was not affected. 
Although NEURL4 may interact with p53 independently of the E3 ubiquitin ligase 
HERC2, we observed that both proteins are needed to regulate the transcriptional 
activity of p53. Clonogenic assays confirmed the functional relevance of this interaction 
observing a decrease in cell growth by NEURL4 overexpression correlated to the 
increase of cellular cycle inhibitor p21 by p53 activation. Under these conditions, 
NEURL4 activated p53 oligomerization. All these findings identify NEURL4 as a novel 
regulator of the p53’s signaling.
INTRODUCTION
The tumor suppressor p53 plays a central role in 
coordinating cellular responses to stress. p53 functions 
as a transcription factor and, although some effects may 
be independent of its transcriptional activity, the p53-
controlled transactivation of target genes is an essential 
feature in the stress response pathway, determining 
whether cells respond by cycle arrest, apoptosis, 
senescence, autophagy, metabolism and/or DNA repair. 
p53’s ubiquitylation, mediated by E3 ubiquitin ligases 
and its further proteasomal degradation, maintains low 
levels of p53 in unstressed cells. Stress signals, such as 
DNA damage, oncogene activation and hypoxia, promote 
p53 activation. This activation of p53 generally consists 
in its stabilization, binding to a sequence-specific DNA, 
and recruitment of the transcriptional machinery to activate 
the transcription of p53 target genes. During these 
sequential steps, p53 activation is modulated by different 
post-translational modifications, including ubiquitylation, 
phosphorylation, acetylation, sumoylation, methylation, 
and neddylation. p53 controls the expression of genes 
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and miRNAs affecting many important cellular processes 
including proliferation, apoptosis, autophagy, DNA repair, 
metabolism, and cell migration. Many of these processes 
are essential to a variety of human pathologies and 
conditions extending beyond cancer, including ischemia, 
neurodegenerative diseases, stem cell renewal, aging, and 
fertility [1–7].
The p53 signaling is inactivated in most cancers. 
Thus, the TP53 gene is deleted or mutated in approximately 
55% of sporadic human cancers while p53 signaling is 
disrupted by alterations to its many regulators and/or 
targets in the remaining tumors [5, 8, 9]. Therefore, it is 
essential to understand the molecular mechanism by which 
p53 is regulated. Post-translational modifications of p53 are 
important in modulating its tumor suppressive functions 
[10]. During the last years, oligomerization/tetramerization 
of p53 has also emerged as a critical event in order to 
regulate the transcription of target genes, necessary to 
inhibit the tumor growth [11, 12]. Impaired oligomerization 
of p53 is associated with tumor’s progression such as 
it happens in some cases of patients with Li-Fraumeni 
syndrome and Li-Fraumeni-like syndromes [12–14].
The E3 ubiquitin ligase HERC2 interacts with p53 
and regulates its transcriptional activity by stimulating p53’s 
oligomerization [15]. Knowing the regulation of this step 
could be useful as an alternative way to restore p53 activity 
in cells with non-mutated p53. Proteins interacting with 
HERC2 are candidates to regulate p53 oligomerization. The 
adaptor-like protein with six neuralized domains NEURL4 
is a HERC2-interacting protein [16, 17]. In association with 
HERC2, NEURL4 has been identified as a modulator of 
centrosome architecture, through the interaction with the 
centrosomal protein CP110 [17, 18], and of Notch signaling 
through the endosomal pathway [19]. Although HERC2 has 
been involved in other cellular processes such as DNA repair 
or cell cycle progression [20], there is very few information 
about other cellular functions in which NEURL4 could 
participate. We asked whether NEURL4 can interact with p53 
and participate in processes regulated by p53. In this study, 
we report a new function for NEURL4. We demonstrate 
that NEURL4 forms a complex with p53 regulating its 
transcriptional activity, and affecting the expression of genes 
such as p21, p53R2, or p53AIPI. NEURL4’s overexpression 
is enough to inhibit cellular growth. Furthermore, cross-
linking experiments indicated that NEURL4 regulates 
the oligomerization of p53. These results demonstrate that 
NEURL4 is a key component in p53 regulation.
RESULTS
Interaction network between NEURL4, HERC2 
and p53 proteins
NEURL4 interacts with the E3 ubiquitin ligase 
HERC2 [16, 17] and HERC2 is one of binding partners 
of p53 [15]. We wondered about the existence of an 
interaction network between these three proteins. To 
analyze this point, we performed immunoprecipitation 
experiments in human embryonic kidney 293T (HEK-
293T) cells with two different antibodies against HERC2. 
Using an antibody against the amino terminus of 
HERC2 (Bvg9), we observed the coimmunoprecipitation 
of NEURL4 and p53 (Figure 1A) which indicated 
an interaction between HERC2 and NEURL4 and 
p53 proteins. We confirmed these results in human 
osteosarcoma U2OS cells (Figure 1B), showing that this 
interaction is not restricted to HEK-293T cells. When we 
used an antibody against the carboxyl terminus of HERC2 
(Bvg1), the coimmunoprecipitation of p53 was lost 
whereas the interaction between HERC2 and NEURL4 
maintained (Figure 1A) suggesting an interaction 
between HERC2 and NEURL4 independent of p53. This 
observation was later confirmed in human non-small cell 
lung carcinoma H1299 cells which do not express p53. In 
these cells, the interaction between HERC2 and NEURL4 
was also observed (Figure 1C). To understand this 
interaction network, we analyzed the immunoprecipitates 
of NEURL4 but the commercial antibody did not 
immunoprecipitate NEURL4. Alternatively, we expressed 
GFP-NEURL4 fusion protein in H1299 cells and we 
performed pull-down experiments using GFP-Trap, a GFP-
binding protein coupled to agarose beads. We observed 
as GFP-NEURL4 interacted with endogenous HERC2 in 
the absence of p53 (Figure 2A, lane 5) demonstrating the 
existence of a NEURL4-HERC2 complex. Interestingly, 
in cells transfected with GFP-NEURL4 and GST-p53, we 
observed how GST-p53 also pull-downs with NEURL4 
and HERC2 (Figure 2A, lane 6). We repeated these 
experiments after HERC2’s knockdown and we observed 
how GST-p53 interacts with NEURL4 in the absence of 
HERC2 (Figure 2B). Pull-down experiments with GFP-
alone or GFP-NEURL4 confirmed the specificity of this 
interaction (Figure 2C). Altogether, these experiments 
indicate the formation of a NEURL4-p53 complex. To 
determine if NEURL4 is necessary for the HERC2-p53 
interaction, we transfected siRNA to deplete NEURL4 
in U2OS cells and, 72 hours post-transfection, we 
analyzed this interaction by immunoprecipitation using 
an antibody against HERC2. Although in less extension, 
HERC2-p53 interaction was also observed after NEURL4 
depletion (Figure 2D). These data together with the 
interaction between HERC2 and NEURL4 independently 
of p53 (Figure 1B and 2A) and the interaction between 
NEURL4 and p53 independently of HERC2 (Figure 
2B), demonstrate the existence of an interaction network 
between NEURL4, HERC2 and p53 proteins.
To map NEURL4-p53 interaction, we expressed 
GFP-NEURL4 and different GST-p53 fusion proteins 
(Figure 3A) in H1299 cells, and we performed pull-
down experiments using GFP-Trap. We observed that 
GFP-NEURL4 binds to all the GST-p53 fusion proteins 
expressed except for the GST-p53∆N300∆C43 fusion protein 
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(Figure 3A), indicating that the last 43 amino acid residues 
of p53 are essential for the interaction with NEURL4. 
Levels of α-tubulin protein were analyzed as negative 
control. Later, we expressed GST or GST-p53 with 
different constructs ofNEURL4 (Figure 3B). Pull-down 
experiments using glutathione-Sepharose showed that p53 
binds with more affinity to the neuralized domains (NHR) 
3 and 4 of NEURL4 (Figure 3B).
NEURL4 stability and ubiquitin ligase activity of 
HERC2
The interaction between NEURL4 and HERC2 
suggested that NEURL4 could regulate the E3 ubiquitin 
ligase activity of HERC2. To answer this question, 
we analyzed the levels of USP33, a specific substrate 
of the ubiquitin ligase activity of HERC2 [21]. We 
depleted U2OS cells of HERC2 or NEURL4 using RNA 
interference. 72 hours post-transfection, cells were treated 
or not with the proteasome inhibitor MG132 and the 
levels of USP33 were analyzed. Knockdown of HERC2 
increased the levels of USP33 (Figure 4A, lane 2), 
confirming that HERC2 functions as an ubiquitin ligase for 
USP33. Similar results were obtained when the cells were 
treated with MG132 (Figure 4A, lane 5). We also observed 
that HERC2 knockdown affects NEURL4 stability. A 
decrease of NEURL4 amount was observed (Figure 4A, 
lanes 2 and 5). When we analyzed the effect of NEURL4 
depletion, USP33 amount was unaffected (Figure 4A, 
lanes 3 and 6 respect to lanes 1 and 4, respectively), 
indicating that under these conditions NEURL4 did not 
regulate the ubiquitin ligase activity of HERC2. Similar 
results were observed in H1299 cells (Figure 4B). 
Additionally, we tested if USP33 could be involved in the 
regulation of NEURL4 stability. Endogenous levels of 
NEURL4 protein were not affected by USP33 depletion 
(Figure 4C). Altogether, these data show that HERC2 
stabilizes NEURL4 protein and that NEURL4 does not 
affect the ubiquitin ligase activity of HERC2 on USP33.
NEURL4 regulates the transcriptional activity of 
p53
To identify whether NEURL4 could regulate p53 
activity, we analyzed the protein levels of p21. Whereas 
p53 levels were not significantly modified, a great decrease 
in p21 levels was observed after NEURL4 depletion 
in U2OS cells (Figure 5A), suggesting that NEURL4 
could be involved in the regulation of p53 transcriptional 
activity. To confirm this observation, we analyzed if 
NEURL4 overexpression is enough to increase the 
levels of p21 protein. U2OS cells were transfected with 
a plasmid expressing myc-NEURL4. After 48 hours of 
transfection, the levels of p21 protein were analyzed. We 
observed an increase of the levels of p21 protein when 
NEURL4 was overexpressed (Figure 5B). These results 
were also confirmed in other cellular type. H1299 cells 
were transfected with a p53’s plasmid and with increasing 
amounts of a plasmid expressing myc-NEURL4. After 
48 hours of transfection, the levels of p21 protein 
were analyzed. We observed a correlation between the 
increase of the myc-NEURL4 amount and the increase 
of p21 levels (Figure 5C). In agreement with the previous 
observations (Figure 4), levels of HERC2 or USP33 were 
not affected (Figure 5A–5C). To conclude that these 
effects are independent on the p53 stability, experiments 
were performed in U2OS cells using the translational 
inhibitor cycloheximide. Time course experiments with 
cycloheximide after siRNA transfection showed that the 
stability of p53 was not significantly modified by NEURL4 
depletion whereas it was increased by depletion of MDM2, 
a well-known ubiquitin ligase for p53 (Figure 5D).
Figure 1: Interaction network between NEURL4, HERC2, and p53 proteins. (A) Supernatants (input) of lysates from HEK-
293T cells were immunoprecipitated (IP) using two different antibodies against HERC2 (Bvg1 and Bvg9) and analyzed by immunoblotting 
with antibodies against the indicated proteins. Preimmune serum (PI) was used as negative control. Similar experiments were performed in 
U2OS cells (B) and H1299 cells (C).
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These findings would suggest that a NEURL4-
dependent mechanism is involved in the transcriptional 
regulation of p21 by p53. To analyze this, luciferase 
reporter assays were performed in U2OS cells transfected 
with the p21 promoter. We observed a decrease in p21 
promoter activity after NEURL4 depletion (Figure 6A, 
left). Endogenous p21 mRNA levels were also decreased 
by NEURL4 knockdown in U2OS cells (Figure 6B, right) 
correlating with the reduction of p21 protein levels (Figure 
6B, left and center). Similar decreases were observed 
using HERC2 siRNA or both siRNAs conjointly (Figure 
6A and 6B). In parallel experiments, no variations were 
observed in p53-null H1299 cells (Figure 6A, right, and 
6C). These results were also confirmed with other genes 
regulated by p53 such as p53AIP1 and p53R2. Thus, 
NEURL4 depletion reduced significantly the promoter 
activity of p53AIP1 and p53R2 (Figure 6D).
NEURL4 regulates p53 oligomerization and cell 
growth
The interaction network between NEURL4, p53 and 
HERC2 proteins (Figure 1 and 2) and the similar regulation 
of p53 transcriptional activity by NEURL4 and HERC2 
Figure 2: Characterization of the interaction between NEURL4, HERC2, and p53 proteins. (A and C) The specificity of 
the interaction between NEURL4, HERC2 and p53 was tested in p53-null H1299 cells with pull-down experiments. Cells were transfected 
with GFP, GFP-NEURL4, GST and GST-p53 plasmids. 48 h later, cells were lysed and centrifuged. Supernatants (Input) were incubated 
with GFP-Trap, proteins retained on the resin were analyzed by immunoblotting with antibodies against the indicated proteins. Asterisk 
(*) means degradation products. (B) Interaction between NEURL4 and p53. H1299 cells were transfected with non-targeting (NT) or 
HERC2 siRNAs and GFP-NEURL4 and GST-p53 plasmids. 72 h later supernatants were incubated with GFP-Trap and analyzed as above 
is indicated. (D) Interaction between HERC2 and p53 independently of NEURL4. U2OS cells were transfected with non-targeting (NT) 
or NEURL4 siRNAs. 72 h later supernatants were immunoprecipitated with anti-HERC2 (Bvg9) polyclonal antibody and analyzed by 
immunoblotting as above is indicated. Preimmune serum (PI) was used as IgG antibody control.
Oncotarget61828www.impactjournals.com/oncotarget
Figure 3: Interaction domains between p53 and NEURL4. (A) H1299 cells were transfected with GFP-NEURL4 and the 
indicated GST-p53 constructs expressing different regions of p53 fused to GST. Domains of p53 are indicated. GST construct was used 
as negative control. 48 h later, cells were lysed and centrifuged. Supernatants (Input) were incubated with GFP-Trap. Proteins retained 
on the resin were analyzed by immunoblotting with antibodies against the indicated proteins. α-tubulin was analyzed as control of 
unspecific binding. (B) H1299 cells were transfected with GST or GST-p53 and the indicated constructs expressing different regions 
of NEURL4. Neuralized domains (NHR) of NEURL4 are indicated. 48 h later, cells were lysed and centrifuged. Supernatants were 
incubated with Glutathione-Sepharose. Proteins retained on the resin were analyzed by immunoblotting with antibodies against the 
indicated proteins.
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Figure 4: Ubiquitin ligase activity of HERC2 and NEURL4 stability. U2OS cells (A and C) or H1299 cells (B) were transfected 
with non-targeting (NT), HERC2, NEURL4 or USP33 siRNAs. 72 h later, lysates were analyzed by immunoblotting with antibodies against the 
indicated proteins. Before lysis, cells were treated with the proteasome inhibitor MG132 for 6 h. Ran protein was analyzed as loading control.
Figure 5: NEURL4 regulates the levels of p21 protein. (A and D) U2OS cells were transfected with non-targeting (NT), NEURL4 or 
MDM2 siRNAs. 72 h later, lysates were analyzed by immunoblotting with antibodies against the indicated proteins. Levels of p21 protein were 
quantified and normalized with respect to Ran levels. When it is indicated, cells were treated with cycloheximide (20 μg/ml) for the indicated 
times. (B) U2OS cells were transfected with pcDNA3 (-) or myc-NEURL4 (+) plasmids. (C) H1299 cells were transfected with 0.5 μg of p53 
construct and increasing amounts (0.5, 1 and 2 μg) of myc-NEURL4 constructs. 48 h later, lysates from transfected cells were analyzed by 
immunoblotting with antibodies against the indicated proteins. Ran protein was analyzed as loading control. Data are expressed as mean ± S.E.M. 
Statistical analysis was carried out as described under “Materials and Methods”. The differences are shown with respect to NT siRNA. **, p< 0.01.
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(Figure 6) led us to analyze whether NEURL4 could 
regulate p53 activity by a mechanism similar to HERC2. 
Because we had previously demonstrated that HERC2 
modulates p53 activity by regulating its oligomerization 
[15], we decided to analyze if p53 oligomerization was 
also regulated by NEURL4. To this end, we overexpressed 
myc-NEURL4 in H1299 cells. Expression of this plasmid 
significantly increased the levels of p21 protein when p53 
was co-expressed (Figure 7A) and correlating with the 
increase of the p53 transcriptional activity (Figure 7B). 
Figure 6: NEURL4 regulates the transcriptional activity of p53. (A and D) U2OS cells or H1299 cells were transfected with 
non-targeting (NT), NEURL4 (N4) or HERC2 (H2) siRNAs and the luciferase reporter indicated (p21, p53AIPI or p53R2 promoter). 72 h later, 
the luciferase activity was quantified as indicated under “Materials and Methods”. (B) U2OS cells or (C) H1299 cells were transfected with 
non-targeting (NT), NEURL4 (N4) or HERC2 (H2) siRNAs. RT quantitative PCR (RT-qPCR) analysis was performed to analyse gene expression 
of p21. The levels of p21 expression were quantified and normalized with respect to GAPDH gene expression (right panels in B and C). Lysates 
from these cells were also analyzed by immunoblotting with antibodies against the indicated proteins (left panels in B and C). Levels of p21 protein 
were quantified and normalized with respect to Ran levels (central panels in B and C). Data are expressed as mean ± S.E.M. Statistical analysis 
was carried out as described under “Materials and Methods”. The differences are shown with respect to NT siRNA. **, p< 0.01; ***, p< 0.001.
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Under these conditions, p53 oligomerization was analyzed 
using a cross-linking assay [15, 22]. We observed a great 
increase in p53 oligomerization in cells overexpressing 
NEURL4 (Figure 7C). Similar results were observed 
in p53 harboring cells like A549 cells (Figure 7D and 
7E). Altogether these data demonstrate that NEURL4 
expression is sufficient to regulate p53 oligomerization 
and induce its transcriptional activity.
Conjoint depletion of NEURL4 and HERC2 have 
an effect similar on the regulation of p53 transcriptional 
activity that their depletions individual (Figure 6), 
suggesting that both proteins are necessary for this 
regulation. Having in mind this, we asked whether 
HERC2 was required for the increase in p21 levels 
mediated by overexpression of NEURL4 (Figure 7). 
To analyze this point, the effect of HERC2 depletion 
in the p21 protein levels was analyzed in H1299 cells 
expressing myc-NEURL4 and/or p53. We observed that 
HERC2 knockdown inhibited the increase of levels of 
p21 mediated by NEURL4 overexpression when p53 was 
co-expressed (Figure 8A, see lane 7 respect to lane 3). 
Interestingly, when we analyzed p53 oligomerization, we 
also observed that HERC2 knockdown inhibited the p53 
oligomerization mediated by NEURL4 overexpression 
(Figure 8B, see lane 12 respect to lane 6).
Finally, to show the functional importance of the 
regulation of p53 activity by NEURL4, we decided to 
analyze cellular processes regulated by p53 such as cell 
growth. To address this, we analyzed the growth of p53-
null H1299 cells using a clonogenicity assay. As expected, 
the expression of p53 plasmid in H1299 cells reduced the 
number of colonies (Figure 9, left panel). Interestingly, a 
greater decrease in the number of colonies was observed 
when myc-NEURL4 was also expressed, in agreement 
with the increase of cell cycle inhibitor p21 (Figure 5C 
and 7A). Similar results were observed in cells harboring 
p53 when myc-NEURL4 was overexpressed (Figure 9, 
right panels).
DISCUSSION
The tumor suppressor p53 is a transcription factor 
that regulates genes expression involved in cellular 
processes linked to growth suppression. Since activation 
of p53 transcriptional activity requires its oligomerization, 
regulating this step is an important control point. In 
humans, p53 mutations that affect its oligomerization state 
have pathological consequences as observed in patients 
with Li-Fraumeni syndrome [13, 14]. The ubiquitin ligase 
HERC2 is one of the few proteins reported to regulate 
Figure 7: NEURL4 regulates p53 oligomerization. H1299 (A-C) and A549 (D and E) cells were transfected with pcDNA3 
(negative control: -) and the indicated plasmids. (A and D) 24 h later, lysates were analyzed by immunoblotting with antibodies 
against the indicated proteins. Ran protein was analyzed as loading control. (B) Under the same conditions, luciferase activity of p21 
promoter was analyzed as indicated under “Materials and Methods”. (C and E) Lysates from cells transfected with the indicated plasmids 
were incubated with glutaraldehyde (GA) at 0.04% on ice for 30 min, and p53 oligomerization was analyzed by immunoblotting with 
anti-p53 antibody as indicated under “Materials and Methods”. Data are expressed as mean ± S.E.M. Statistical analysis was carried out as 
described under “Materials and Methods”. *, p< 0.05; ***, p< 0.001.
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p53 oligomerization [15]. The adaptor-like protein with 
six neuralized domains NEURL4 is a HERC2-interacting 
protein [16, 17, 23] that modulates of centrosome 
architecture through the interaction with the centrosomal 
protein CP110 [17, 18]. Now, this study reports the 
existence of an interactions network between NEURL4, 
HERC2 and p53 proteins. Structurally, our results indicate 
that each one of these three proteins may interact with each 
other two independently. Interestingly, NEURL4 (Figure 
3A) and HERC2 [15] interact with the same region of p53. 
Through these interactions, the transcriptional activity 
of p53 is regulated. Proteins assemble into complexes 
to exert their functions within the cell. Experiments of 
size exclusion chromatography previously demonstrated 
a similar elution profile for HERC2 and NEURL4, 
being part of a high-molecular mass complex of about 
2 MDa [16]. These data together with the observation 
that the depletion of HERC2 and/or NEURL4 inhibited 
Figure 8: HERC2 is required for the regulation of p53 activity mediated by NEURL4. H1299 cells were transfected with 
plasmids and siRNAs which are indicated. 72 h later, lysates were analyzed by immunoblotting with antibodies against the indicated 
proteins (A) or by protein cross-linking assay (B) as described under “Materials and Methods”.
Figure 9: NEURL4 regulates cell growth. Colony formation assays were performed in cells transfected with the indicated plasmids. 
24 h later, G418 antibiotic was added (at 400, 500 or 700 μg/ml for U2OS, H1299 or A549 cells, respectively) and maintained for 12-15 
days. After this time, cells were stained with crystal violet as indicated under “Materials and Methods”.
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in a similar extension the transcriptional activity of p53, 
suggest a coordinated function of these proteins on p53. 
The interaction of NEURL4 with the C-terminal amino 
acid residues of p53 enclosing part of its tetramerization 
domain would suggest the involvement of NEURL4 in p53 
oligomerization. This hypothesis could be demonstrated 
using cross-linked studies with glutaraldehyde. Thus, we 
show that NEURL4 regulates p53 oligomerization.
Mutations located within the p53 tretamerization 
domain disrupt p53 oligomerization [12]. Interestingly, 
p53 acetylation does not occur on p53 mutants that are 
incapable of forming oligomers because acetyltransferases 
cannot interact [12]. p53 acetylation is indispensable for 
its activation [11]. These observations suggest a model for 
p53 activation in which p53 oligomerization precedes its 
acetylation and activation [12]. Our findings incorporate 
HERC2 and NEURL4 to this model functioning like 
necessary cofactors for p53 oligomerization.
HERC2 through its ubiquitin ligase activity may 
label proteins such as USP33 with ubiquitin for ubiquitin-
dependent proteasomal degradation [21]. Although it has 
been reported that NEURL4 is ubiquitylated in a HERC2-
depedent manner [17], we observe that neither NEURL4 
levels neither p53 levels were increased after HERC2 
knockdown. In fact, NEURL4 was destabilized in absence 
of HERC2. These data are in agreement with previous 
observations [15–17] confirming that HERC2 does not 
regulate p53 levels and suggesting that HERC2-dependent 
NEURL4 ubiquitylation must serve a different purpose 
than regulating NEURL4 levels. NEURL4 could also act 
as a regulator of the ubiquitin ligase activity of HERC2. 
In fact, a role as an adaptor bringing substrates to the 
E6AP and HERC2 ubiquitin ligases had been previously 
suggested [24]. Although this possibility is attractive, 
the stability of USP33 levels after NEURL4 depletion 
would indicate that NEURL4 is probably not involved 
in processes regulated by the ubiquitin ligase activity of 
HERC2 such as the modulation of iron metabolism [25, 
26] or the response to DNA damage [27–31].
NEURL4 has been recently identified as a member of 
the superfamily of ADP-ribosyltransferases [23]. However, 
this activity and their biological implications have not been 
studied. NEURL4 has been implicated in the centrosome 
assembly [17, 18] and more recently in Notch signaling 
[19]. Our results identify a new function for NEURL4 as 
a regulator of p53 activity. p53 controls the expression 
of genes and miRNAs affecting many important cellular 
processes including proliferation, DNA repair, apoptosis, 
autophagy, metabolism or cell migration [3–5]. NEURL4 
through the regulation of p53 activity could be involved in 
some of these cellular processes. Although more studies 
will be necessary to know the NEURL4 relevance in 
these cellular processes, the demonstration that NEURL4 
expression regulated cell growth, shows an important 
and unknown role of NEURL4 in proliferation. These 
characteristic points out that NEURL4 could function as 
a tumor suppressor protein. Consequently, deletions of 
NEURL4 gene could enhance tumorigenesis in some types 
of cancer. Interestingly, analysis of cancer genomics data 
sets from the cBioPortal (http://www.cbioportal.org/) shows 
a high frequency in NEURL4 deletions in three different 
studies (TCGA2015, MICH and TCGA) of prostate cancer 
[32, 33].
In conclusion, we identify a new function 
for NEURL4 as a regulator of p53 signaling. We 
demonstrated that NEURL4 interacts with p53 and 
regulates its transcriptional activity through modulation 
of its oligomerization. Our data contribute to clarify 
the activation model of p53 as well as pointing out 
pathological consequences of the NEURL4 dysregulation.
MATERIALS AND METHODS
Reagents
The following reagents were used: anti-HERC2 
monoclonal (BD Biosciences #612366); anti-HERC2 
polyclonal (Bvg1 antibodies against residues 4785-
4834, and Bvg9 antibodies against residues 1-199) [15]; 
anti-p21 (C-19), anti-p53 (FL-393), anti-NEURL4 (E-20) 
(Santa Cruz Biotechnology, Inc.); anti-p53 Ab-5 (DO-
7) (Neo Markers); anti-GST monoclonal (GenScript); 
anti-Ran [34]; anti-α-tubulin (Ab-1) (Calbiochem); anti-
USP33 (Proteintech); anti-Flag M2 (Sigma); anti-GFP 
and anti-c-myc (clone 9E10) (Roche); anti-MDM2 (2A10) 
(Abcam); Z-Leu-Leu-Leu-al (MG132) (Sigma-Aldrich); 
horseradish peroxidase-conjugated secondary antibodies; 
lipofectamine LTX (Invitrogen); cycloheximide 
(Applichem); protein A-Sepharose and glutathione-
Sepharose (GE Healthcare); GFP-Trap_A (ChromoTek); 
Immobilon-P PVDF transfer membrane (Millipore 
Corporation); luciferase assay system (Promega); 
luminescent β-galactosidase detection Kit II (Clontech 
Laboratories).
Plasmids and siRNAs
pEGB–p53 constructs (WT, ΔN200, ΔN300 
and ΔN300ΔC43), p53 construct (WT), luciferase 
reporters (p21WAF1, p53AIPI and p53R2), GFP-
NEURL4 construct and myc-NEURL4 construct 
and NEURL4 constructs (full-length, NHR 1-2, 
NHR 3-4 and NHR 5-6) were kindly provided by 
Dr Y. Xiong [35], Dr. Y. Zhang [12], Dr Y. Taya [36], 
Dr. L. Pelletier [17] and Drs. Y. Imai and R. Takahashi 
[19], respectively. siRNAs targeting the human sequence 
of HERC2 (H2.2: GACUGUAGCCAGAUUGAAA); 
NEURL4 (CCAUCAUGCAAGACGGUAA); USP33 
(GAUCAUGUGGCGAAGCAUA); MDM2 (UGGU-
UGCAUUGUCCAUGGC) and a non-targeting siRNA 
(NT: UAGCGACUAAACACAUCAA) were purchased 
from GenePharma.
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Cell culture, transfections and clonogenic assays
HEK-293T, U2OS, A549 and H1299 human 
cells from ATCC were cultured at 37°C in Dulbecco’s 
modified Eagle’s medium (DMEM) (Gibco) with 10% 
fetal bovine serum. The transfection of cells (plasmids 
and siRNAs) was carried out using calcium phosphate 
[15] or lipofectamine LTX according to instructions of 
the fabricant. The final concentration of siRNAs was 100 
nM and the total plasmid DNA 2 μg (for lipofectamine 
LTX) or 4 μg (for calcium phosphate) into a well of a 
6-well plate. When it was necessary for the experiments, 
10 ng of p53 construct was transfected in H1299 cells. 
Cells transfected with plasmids were analyzed after 24-48 
hours of the transfection. Cells transfected with plasmids 
and siRNAs or only siRNAs were recovered at 72 h post-
transfection. MG132 was added to the cells for 6 h to a 
final concentration of 10 μM. For clonogenic assays, cells 
into 6-well plates at 50% confluence were transfected with 
pcDNA3 and the indicated plasmids using lipofectamine 
LTX. 24 hours later, the cells were trypsined and seeded 
(1/10) into 10 cm-diameter plates. 24 hours later, G418 
antibiotic was added (at 400, 500 or 700 μg/ml for U2OS, 
H1299 or A549 cells, respectively) and maintained for 12-
15 days. After this time, the cells were stained with crystal 
violet as previously described [15].
Cell lysate and immunoblotting
Cells were lysed with NP40 buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 50 mM NaF, 0.5% NP40) 
containing protease and phosphatase inhibitors (50 
mM β-glycerophosphate, 1 mM sodium vanadate, 1 
mM phenylmethylsulfonyl fluoride, 5 μg/ml leupeptin, 
5 μg/ml aprotinin, 1 μg/ml pepstatin A and 100 μg/
ml benzamidine). Cell lysates were sonicated on ice 
and maintained under agitation for 20 min. The lysates 
were then centrifuged at 13,000 x g at 4°C for 10 min, 
and the supernatants were collected to be analyzed by 
electrophoresis and immunoblot using the Tris-acetate 
PAGE system [37]. Band intensities were analyzed using 
a gel documentation system (LAS-3000 Fujifilm). Protein 
levels were normalized with respect to Ran levels and 
expressed as a percentage of controls.
Immunoprecipitations and pull-down 
experiments
For immunoprecipitation (IP), supernatants (input) 
were incubated with preimmune serum (PI) or with 
anti-HERC2 polyclonal antibodies (Bvg1 or Bvg9) 
for 2 h at 4ºC with gentle agitation. Antibodies were 
immunoprecipitated with protein A-Sepharose for 1 h 
at 4ºC. Beads were pelleted by centrifugation at 2,500 
x g, washed five times with NP40 buffer, and analyzed 
by electrophoresis and immunoblot as it was indicated 
above. For pull-down experiments, supernatants (input) 
were incubated with GFP-Trap or Glutathione-Sepharose 
beads overnight at 4°C. Pellets were washed five times 
with NP40 buffer and analyzed by electrophoresis and 
immunoblot as it was indicated above.
Protein cross-linking assay
After lysis, the cells were centrifuged and the 
supernatant was recovered. Glutaraldehyde was added 
to the supernatant at the indicated concentrations and 
incubated on ice for 30 min. Cross-linking reaction was 
stopped by adding sample buffer (1x final concentration), 
and the samples were analyzed by electrophoresis 
and immunoblot, similarly as it was described 
previously [15].
Luciferase assay
U2OS or H1299 cells were transfected with the 
corresponding reporter (0.4 μg of reporter and 0.2 μg 
CMV-βgal). Luciferase activity was quantified using the 
Luciferase Assay System (Promega). Luciferase values 
were normalized using β-galactosidase activity measured 
using the Luminescent β-galactosidase Detection Kit II 
(Clontech Laboratories). Luminescent levels are expressed 
as a percentage of controls.
Reverse transcriptase quantitative PCR 
(RT-qPCR) analysis
Total RNA was isolated from transfected cells using 
Trisure reagent (Bioline) according to the manufacturer’s 
protocol. 2 μg of total RNA were reverse-transcribed using 
the high capacity cDNA Reverse Transciption kit (Applied 
Biosystems). Quantitative PCR was carried out using 
ABI Prism 7900 HT Fast Real-Time PCR System, and 
commercially available human TaqMan assays (Applied 
Biosystems) were used to quantify gene expression of 
CDKN1A (p21) (Hs00355782_m1) and the housekeeping 
gene GAPDH (HS99999905_m1) was used to normalize 
them. PCR data were captured and analyzed using the 
Sequence Detector software (SDS version 2.3; Applied 
Biosystems).
Statistical analysis
Results are expressed as mean ± S.E.M. Data for 
multiple variable comparisons were analyzed by one-
way analysis of variance (ANOVA). For comparison 
of significance, Dunnet’s test or Tukey’s test were used 
according to the statistical program GraphPad Prism.
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